Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $4

Futu NewsJan 10 23:33 · Ratings

Optimistic Outlook for Passage Bio: Buy Rating Justified by Promising Clinical Results and Extended Cash Runway

TipRanksJan 10 23:25 · Ratings

Passage Bio Restructures and Extends Cash Runway

TipRanksJan 10 20:29

Passage Bio Says It Has Reviewed Its Operating Needs And Will Transition To An Outsourced Analytical Testing Model. This Transition, Coupled With An Associated Reduction In Workforce Of Approximately 55% And Reductions In Operating Expenses, Extends...

BenzingaJan 10 20:27

Passage Bio Reported Updated Data From The Ongoing Phase 1/2 UpliFT-D Trial Of PBFT02 For Frontotemporal Dementia With Granulin Mutations

BenzingaJan 10 20:25

Express News | Passage Bio : To Reduce Operating Costs and Better Align Its Workforce With Needs of Its Strategic Research and Development Strategy

BreakingsJan 10 20:12